07:16 AM EDT, 08/01/2024 (MT Newswires) -- Moderna ( MRNA ) reported a Q2 loss Thursday of $3.33 per diluted share, narrowing from a loss of $3.62 a year earlier.

Analysts polled by Capital IQ expected a loss of $3.35 per share.

Revenue for the quarter ended June 30 was $241 million, down from $344 million a year earlier.

Analysts surveyed by Capital IQ expected $134.9 million.

The pharmaceutical company said it expects 2024 product sales of its respiratory infections vaccines of $3 billion to $3.5 billion.

Shares of the company were down nearly 12% in recent Thursday premarket activity.

Price: 104.99, Change: -14.23, Percent Change: -11.94